Thomas E Keane
Overview
Explore the profile of Thomas E Keane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
848
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crawford E, Hafron J, Tagawa S, Twardowski P, Harris R, Moul J, et al.
J Urol
. 2020 Oct;
205(2):554-560.
PMID: 33090917
Purpose: Nonadherence to dosing schedules for androgen deprivation therapy increases the risk of testosterone escape for patients with prostate cancer. Two approved formulations of leuprolide acetate, the most commonly prescribed...
2.
Crawford E, Andriole G, Freedland S, Garnick M, Gomella L, Henderson J, et al.
Can J Urol
. 2020 Oct;
27(5):10352-10362.
PMID: 33049187
Materials And Methods: Literature review. Results: Critical goals in prostate cancer management include preventing or delaying emergence of distant metastases and progression to castration-resistant disease. Pathways for progression to metastatic...
3.
Crawford E, Twardowski P, Concepcion R, Hafron J, Harris R, Moul J, et al.
J Urol
. 2019 Oct;
203(4):743-750.
PMID: 31580749
Purpose: We evaluated the timeliness of androgen deprivation therapy dosing, the impact of dosing nonadherence on testosterone, and the frequency of testosterone and prostate specific antigen testing in patients with...
4.
A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III)
Crawford E, Koo P, Shore N, Slovin S, Concepcion R, Freedland S, et al.
J Urol
. 2018 Aug;
201(4):682-692.
PMID: 30077557
Purpose: The advanced prostate cancer therapeutic landscape has changed dramatically in the last several years, resulting in improved overall survival of patients with castration naïve and castration resistant disease. The...
5.
Greiman A, Keane T
Curr Urol Rep
. 2017 Apr;
18(6):41.
PMID: 28417429
Purpose Of Review: Androgen deprivation therapy (ADT) is a mainstay of treatment for advanced prostate cancer. Several studies have reported an association between ADT and an increase in cardiovascular events,...
6.
Crawford E, Schally A, Pinthus J, Block N, Rick F, Garnick M, et al.
Urol Oncol
. 2017 Mar;
35(5):183-191.
PMID: 28325650
Purpose: To explore how follicle-stimulating hormone (FSH) may contribute to cardiovascular, metabolic, skeletal, and cognitive events in men treated for prostate cancer, with various forms of androgen deprivation therapy (ADT)....
7.
Crawford E, Petrylak D, Shore N, Saad F, Slovin S, Vogelzang N, et al.
Urology
. 2017 Mar;
104:150-159.
PMID: 28302580
Objective: To offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostate cancer (CRPC) treatments. Materials And Methods: The...
8.
Greiman A, Shah J, Bhavsar R, Armeson K, Caulder S, Jones R, et al.
Urology
. 2016 Jan;
90:32-7.
PMID: 26802800
Objective: To evaluate asymptomatic men with elevated serum prostate-specific antigen (PSA) to determine whether a 6-week course of fluoroquinolone antibiotics lowers serum PSA and affects recommendations for prostate biopsy. Materials...
9.
Shore N, Karsh L, Gomella L, Keane T, Concepcion R, Crawford E
BJU Int
. 2015 Mar;
115(2):188-97.
PMID: 25756134
Prostate cancer is one of the most common cancers diagnosed in men in the USA and 20–30% of men treated for localised prostate cancer will fail therapy and develop advanced...
10.
Crawford E, Stone N, Yu E, Koo P, Freedland S, Slovin S, et al.
Urology
. 2014 Jan;
83(3):664-9.
PMID: 24411213
Prostate cancer is often associated with metastases to bone and/or soft tissue. The progression to metastatic castrate-resistant prostate cancer is a seminal event in disease progression affecting treatment decisions. A...